Gilead Extends Push Into Oncology With Agenus R&D Pact

Allying itself with US biotech Agenus underscores Gilead's oncology ambitions, which incoming CEO-designate Daniel O'Day must make good on.

SyringeClinic
R&D Pact Provides Gilead Options To 3 Agenus immuno-oncology Assets • Source: Shutterstock

Gilead Sciences Inc. signaled its continuing push into cancer immunotherapy by inking a deal with Agenus Inc. to develop and commercialize up to five novel immuno-oncology treatments, an arrangement potentially worth more than $1.8bn for the Lexington, Massachusetts-based biotech.

For Gilead, the R&D pact with immunotherapy specialist Agenus is its latest effort to enter the oncology field and help...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.